Chembio Diagnostic Systems, Inc. (CDS) was founded in 1985 and is headquartered in Medford, New York. It operates as a subsidiary of Chembio Diagnostics, Inc. (Nasdaq: CEMI), where it develops, manufactures, licences and markets proprietary rapid diagnostic tests. CDS has developed a patented breakthrough Point-of-Care (POC) test, known as the Dual Path Platform (DPP®) technology that offers significant advantages over lateral-flow technologies. This is demonstrated by having an improvement in sensitivity and multiplexing, establishing a new pipeline of business opportunities and potential products. Today, the DPP® technology forms the basis of multiple collaborations with healthcare innovators worldwide focusing on infectious diseases such as HIV, Syphilis, Dengue, Zika and other febrile illnesses. This further cements the company as a leader in POC rapid diagnostic tests for infectious diseases. CDS is also licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485.